Lack of potentiation of vincristine-induced neurotoxicity by VP-16–213

Publisher Website
Google Scholar
Abstract
The neurologic toxicity data from a randomized trial of vincristine and VP-16-213 in small cell carcinoma of the lung were analyzed. Of 102 patients evaluable for toxicity, 50 were treated with a combination of cyclophosphamide, adriamycin, and vincristine (CAV) and 52 received this regimen plus VP-16-213. Vincristine dosage was the same in both arms of the study. When analyzed by severity, neurologic complications were similar in both treatment groups: Grade 1-2 neurotoxicity occurred in 55% of patients on both arms and grade 3-4 neurotoxicity was observed in 6 (12%) patients on the CAV arm and 4 (8%) on the CAV-VP-16-213 arm. Addition of VP-16-213 to vincristine did not potentiate vincristine-induced neurotoxicity when administered in this dose-schedule relationship.

This publication has 0 references indexed in Scilit: